Stock XVIVO XVIVO PERFUSION AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Xvivo Perfusion AB

Equities

XVIVO

SE0004840718

Real-time Estimate Cboe Europe
Other stock markets
 11:06:00 2024-04-29 am EDT 		5-day change 1st Jan Change
376.2 SEK +0.87% Intraday chart for Xvivo Perfusion AB +19.75% +14.11%
Apr. 24 Nordic Shares Declined Wednesday; Svenska Handelsbnkn Ser A Fell Furthest DJ
Apr. 24 Transcript : Xvivo Perfusion AB, Q1 2024 Earnings Call, Apr 24, 2024

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company returns high margins, thereby supporting business profitability.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 158.8 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
XVIVO PERFUSION AB Stock Xvivo Perfusion AB
+14.11% 1.07B
B
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.11% 187B
C+
MEDTRONIC PLC Stock Medtronic plc
-1.92% 106B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.05% 66.9B
A
DEXCOM, INC. Stock DexCom, Inc.
-0.57% 49.45B
B-
CENCORA, INC. Stock Cencora, Inc.
+16.30% 48B
B-
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+3.63% 26.48B
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+1.49% 26.25B
A-
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
A-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. XVIVO Stock
  4. Ratings Xvivo Perfusion AB